Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.

ABSTRACT:

SUBMITTER: Hughes DA 

PROVIDER: S-EPMC6593787 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature